StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

ORIGINAL · NewsquawkEli Lilly (LLY) to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesityRead originalHide original

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials

StockNow breaking-news AI analysis

Lilly’s item reports substantial knee-pain and weight reductions with retatrutide in two Phase 3 trials, while providing no numerical results or detailed Taltz and Zepbound findings.

News detail

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials

1 stocks
LLYEli Lilly & Co.$1,432.84Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Senior US officials see a high probability of war with Iran, N12 TV reports

Geopolitics

Pakistan's Deputy PM and Foreign Minister met Iran's ambassador and held separate calls with his Saudi and Omani counterparts over the past 24 hours to discuss regional de-escalation, Pakistani journalist Mallick reports

Fed

Fed's Hammack (hawkish dissenter) says gradual rate hikes less disruptive to economy and financial system and monetary policy needs to move to restrictive stance